Managing multiple clinical studies through various phases of development across multiple sites is a complex operation.
Moreover, when each study uses its own supply of drugs and is managed in its own standalone IRT system, the complications and inefficiencies multiply – both for the Sponsor and investigators. To overcome this challenge, Blueprint Medicines turned to endpoint Clinical for help on creating a unified, seamless technology experience for all the company’s studies, notably to include early phase, investigator-initiated, and compassionate use studies.
Call us from within the United States:
Calling from outside the United States?